-
Vericiguat
API’s Name Indication Innovator Patent Expiry Date(The U.S) Vericiguat Heart failure Bayer and MSD May. 24, 2031 -
Abrocitinib
API’s Name Indication Innovator Patent Expiry Date(The U.S) Abrocitinib Atopic Dermatitis Pfizer Feb.11, 2034 -
Rimegepant
API’s Name Indication Innovator Patent Expiry Date(The U.S) Rimegepant Migraine headache Biohaven Feb. 22, 2031 -
Elagolix 834153-87-6
API’s Name Indication Specification US DMF EU DMF CEP Elagolix CAS: 834153-87-6 Endometriosis In-House -
Relugolix 737789-87-6
API’s Name Indication Specification US DMF EU DMF CEP Ribociclib CAS: 737789-87-6 Antineoplastic In-House -
Venetoclax 1257044-40-8
API’s Name Indication Innovator Patent Expiry Date(The U.S) Venetoclax 1257044-40-8 CLL Abbvie Jun.27,2031 -
Velpatasvir(PVP)
API’s Name Indication Specification US DMF EU DMF CEP Velpatasvir(PVP) HCV In-House √ -
Thalidomide
API’s Name Indication Specification US DMF EU DMF CEP Thalidomide Oncology drug USP/EP -
Ticagrelor
API’s Name Indication Specification US DMF EU DMF CEP Ticagrelor Anticoagulant In-House 28984 √ -
Tofacitnib Citrate
API’s Name Indication Specification US DMF EU DMF CEP Tofacitnib Citrate Rheumatoid arthritis In-House -
Sugammadex Sodium
API’s Name Indication Specification US DMF EU DMF CEP Sugammadex Sodium Neuromuscular blockade In-House